NDATOPICALAEROSOL, FOAM
Approved
Jan 2006
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
5
Data completeness
3/8 — Basic
MEN'S ROGAINE (minoxidil) by Design Pharmaceuticals is clinical pharmacology 1. First approved in 2006.
Drug data last refreshed 7h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Men's Rogaine is a topical foam formulation of minoxidil, a small-molecule vasodilator originally developed for oral hypertension treatment. It is indicated for androgenetic alopecia (male pattern baldness) in men, working by enhancing microcirculatory blood flow to hair follicles to stimulate regrowth. The topical application bypasses systemic effects while delivering the active compound directly to the scalp.
LOE Approaching
Product approaching loss of exclusivity with moderate competitive pressure (30/100), suggesting transition planning and cost-containment focus for remaining brand team.
Mechanism of Action
CLINICAL PHARMACOLOGY 1. General Pharmacologic Properties Minoxidil is an orally effective direct acting peripheral vasodilator that reduces elevated systolic and diastolic blood pressure by decreasing peripheral vascular resistance. Microcirculatory blood flow in animals is enhanced or maintained…
Worked on MEN'S ROGAINE at Design Pharmaceuticals? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.